This event reflects a strategic moment in the bio-pharmaceutical industry’s engagement with public trust and global health equity. The strongest version of this narrative is that industry leaders, policymakers, and academics are proactively addressing systemic challenges—such as drug pricing, transparency, and access—through reform and dialogue. GlaxoSmithKline’s reforms, as outlined by Witty, suggest a shift toward greater accountability, which could serve as a model for the sector. The inclusi...